Resveratrol ameliorates hepatic steatosis and inflammation in methionine/choline-deficient diet-induced steatohepatitis through regulating autophagy

Lipids in Health and Disease

Volumn 14, Issue 1, 2015, Pages

  Ji, Guiyuan ^a   Wang, Yuqi ^a,b   Deng, Yingxun ^b   Li, Xin ^a   Jiang, Zhuoqin ^b  

^a GUANGZHOU CENTER FOR DISEASE CONTROL AND PREVENTION   (China)

^b SUN YAT SEN UNIVERSITY   (China)

Author keywords

Autophagy; Hepatic inflammation; Hepatic steatosis; IL 1 ; IL 6; Methionine choline deficient; Non alcoholic steatohepatitis; Resveratrol; TBARS; TNF

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; CHOLINE; CYTOKINE; INTERLEUKIN 1BETA; INTERLEUKIN 6; LIPID; MESSENGER RNA; METHIONINE; PHYTOALEXIN; RESVERATROL; THIOBARBITURIC ACID REACTIVE SUBSTANCE; TRIACYLGLYCEROL; TUMOR NECROSIS FACTOR ALPHA; NONSTEROID ANTIINFLAMMATORY AGENT; STILBENE DERIVATIVE;

ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; AUTOPHAGY; CELL CULTURE; CONTROLLED STUDY; DISEASE COURSE; DOWN REGULATION; DRUG MECHANISM; FATTY LIVER; IN VITRO STUDY; IN VIVO STUDY; INFLAMMATION; LIPID STORAGE; LIVER INJURY; MALE; MOUSE; NONHUMAN; OXIDATION; PROTEIN ANALYSIS; PROTEIN EXPRESSION; TRIACYLGLYCEROL BLOOD LEVEL; ANIMAL; BLOOD; C57BL MOUSE; COMPLICATION; DEFICIENCY; DRUG EFFECTS; GENE EXPRESSION; GENETICS; IMMUNOLOGY; NON-ALCOHOLIC FATTY LIVER DISEASE; OXIDATIVE STRESS; PRECLINICAL STUDY; VITAMIN DEFICIENCY;

ANIMALS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; AUTOPHAGY; CHOLINE DEFICIENCY; CYTOKINES; DRUG EVALUATION, PRECLINICAL; GENE EXPRESSION; MALE; METHIONINE; MICE, INBRED C57BL; NON-ALCOHOLIC FATTY LIVER DISEASE; OXIDATIVE STRESS; STILBENES;

EID: 84945119035     PISSN: None     EISSN: 1476511X     Source Type: Journal    
DOI: 10.1186/s12944-015-0139-6     Document Type: Article

References (37)

1. Browning JD. Statins and hepatic steatosis: perspectives from the Dallas Heart Study. Hepatology. 2006;44(2):466-71.
2. Mavrogiannaki AN, Migdalis IN. Nonalcoholic Fatty Liver Disease, Diabetes Mellitus and Cardiovascular Disease: Newer Data. Int J Endocrinol. 2013; doi:10.1155/2013/450639.
3. Day CP. Natural history of NAFLD: remarkably benign in the absence of cirrhosis. Gastroenterology. 2005;129(1):375-8.
4. Tarantino G, Savastano S, Colao A. Hepatic steatosis, low-grade chronic inflammation and hormone/growth factor/adipokine imbalance. World J Gastroenterol. 2010;16(38):4773-83.
5. Asrih M, Jornayvaz FR. Inflammation as a potential link between nonalcoholic fatty liver disease and insulin resistance. J Endocrinol. 2013;218(3):R25-36.
6. Guo H, Xia M, Zou T, Ling W, Zhong R, Zhang W. Cyanidin 3-glucoside attenuates obesity-associated insulin resistance and hepatic steatosis in high-fat diet-fed and db/db mice via the transcription factor FoxO1. J Nutr Biochem. 2012;23(4):349-60.
7. Xiao CW, Wood CM, Weber D, Aziz SA, Mehta R, Griffin P, et al. Dietary supplementation with soy isoflavones or replacement with soy proteins prevents hepatic lipid droplet accumulation and alters expression of genes involved in lipid metabolism in rats. Genes Nutr. 2014;9(1):373.
8. Jang HH, Park MY, Kim HW, Lee YM, Hwang KA, Park JH, et al. Black rice (Oryza sativa L.) extract attenuates hepatic steatosis in C57BL/6 J mice fed a high-fat diet via fatty acid oxidation. Nutr Metab (Lond). 2012;9(1):27.
9. Baur JA, Sinclair DA. Therapeutic potential of resveratrol: the in vivo evidence. Nat Rev Drug Discov. 2006;5(6):493-506.
10. Qureshi AA, Guan XQ, Reis JC, Papasian CJ, Jabre S, Morrison DC, et al. Inhibition of nitric oxide and inflammatory cytokines in LPS-stimulated murine macrophages by resveratrol, a potent proteasome inhibitor. Lipids Health Dis. 2012;11:76.
11. Chen Q, Wang E, Ma L, Zhai P. Dietary resveratrol increases the expression of hepatic 7alpha-hydroxylase and ameliorates hypercholesterolemia in high-fat fed C57BL/6 J mice. Lipids Health Dis. 2012;11:56.
12. Signorelli P, Ghidoni R. Resveratrol as an anticancer nutrient: molecular basis, open questions and promises. J Nutr Biochem. 2005;16(8):449-66.
13. Di Pascoli M, Divi M, Rodriguez-Vilarrupla A, Rosado E, Gracia-Sancho J, Vilaseca M, et al. Resveratrol improves intrahepatic endothelial dysfunction and reduces hepatic fibrosis and portal pressure in cirrhotic rats. J Hepatol. 2013;58(5):904-10.
14. Salado C, Olaso E, Gallot N, Valcarcel M, Egilegor E, Mendoza L, et al. Resveratrol prevents inflammation-dependent hepatic melanoma metastasis by inhibiting the secretion and effects of interleukin-18. J Transl Med. 2011;9:59.
15. Zhang Y, Chen ML, Zhou Y, Yi L, Gao YX, Ran L, et al. Resveratrol improves hepatic steatosis by inducing autophagy through the cAMP signaling pathway. Mol Nutr Food Res. 2015;59(8):1443-57.
16. Zhu W, Chen S, Li Z, Zhao X, Li W, Sun Y, et al. Effects and mechanisms of resveratrol on the amelioration of oxidative stress and hepatic steatosis in KKAy mice. Nutr Metab (Lond). 2014;11:35.
17. Andrade JM, Paraiso AF, de Oliveira MV, Martins AM, Neto JF, et al. Resveratrol attenuates hepatic steatosis in high-fat fed mice by decreasing lipogenesis and inflammation. Nutrition. 2014;30(7-8):915-9.
18. Chachay VS, Macdonald GA, Martin JH, Whitehead JP, O'Moore-Sullivan TM, Lee P, et al. Resveratrol does not benefit patients with nonalcoholic fatty liver disease. Clin Gastroenterol Hepatol. 2014;12(12):2092-2103 e2091-2096.
19. Shen B, Yu J, Wang S, Chu ES, Wong VW, Zhou X, et al. Phyllanthus urinaria ameliorates the severity of nutritional steatohepatitis both in vitro and in vivo. Hepatology. 2008;47(2):473-83.
20. Poulsen MM, Larsen JO, Hamilton-Dutoit S, Clasen BF, Jessen N, Paulsen SK, et al. Resveratrol up-regulates hepatic uncoupling protein 2 and prevents development of nonalcoholic fatty liver disease in rats fed a high-fat diet. Nutr Res. 2012;32(9):701-8.
21. Jeon BT, Jeong EA, Shin HJ, Lee Y, Lee DH, Kim HJ, et al. Resveratrol attenuates obesity-associated peripheral and central inflammation and improves memory deficit in mice fed a high-fat diet. Diabetes. 2012;61(6):1444-54.
22. Xin P, Han H, Gao D, Cui W, Yang X, Ying C, et al. Alleviative effects of resveratrol on nonalcoholic fatty liver disease are associated with up regulation of hepatic low density lipoprotein receptor and scavenger receptor class B type I gene expressions in rats. Food Chem Toxicol. 2013;52:12-8.
23. Scicchitano P, Cameli M, Maiello M, Modesti PA, Muiesan ML, Novo S, et al. Nutraceuticals and dyslipidaemia: Beyond the common therapeutics. Journal of Functional Foods. 2014;6:11-32.
24. Faghihzadeh F, Adibi P, Rafiei R, Hekmatdoost A. Resveratrol supplementation improves inflammatory biomarkers in patients with nonalcoholic fatty liver disease. Nutr Res. 2014;34(10):837-43.
25. Pan QR, Ren YL, Liu WX, Hu YJ, Zheng JS, Xu Y, et al. Resveratrol prevents hepatic steatosis and endoplasmic reticulum stress and regulates the expression of genes involved in lipid metabolism, insulin resistance, and inflammation in rats. Nutr Res. 2015;35(7):576-84.
26. Heeboll S, Thomsen KL, Clouston A, Sundelin EI, Radko Y, Christensen LP, et al. Effect of resveratrol on experimental non-alcoholic steatohepatitis. Pharmacol Res. 2015;95-96:34-41.
27. Heeboll S, El-Houri RB, Hellberg YE, Haldrup D, Pedersen SB, Jessen N, et al. The effect of resveratrol on experimental non-alcoholic fatty liver disease depends on severity of pathology and timing of treatment. J Gastroenterol Hepatol. 2015; doi:10.1111/jgh.13151
28. Singh R, Kaushik S, Wang Y, Xiang Y, Novak I, Komatsu M, et al. Autophagy regulates lipid metabolism. Nature. 2009;458(7242):1131-5.
29. Hernandez-Gea V, Ghiassi-Nejad Z, Rozenfeld R, Gordon R, Fiel MI, Yue Z, et al. Autophagy releases lipid that promotes fibrogenesis by activated hepatic stellate cells in mice and in human tissues. Gastroenterology. 2012;142(4):938-46.
30. Kim ES, Chang H, Choi H, Shin JH, Park SJ, Jo YK, et al. Autophagy induced by resveratrol suppresses alpha-MSH-induced melanogenesis. Exp Dermatol. 2014;23(3):204-6.
31. Chang YP, Ka SM, Hsu WH, Chen A, Chao LK, Lin CC, et al. Resveratrol inhibits NLRP3 inflammasome activation by preserving mitochondrial integrity and augmenting autophagy. J Cell Physiol. 2015;230(7):1567-79.
32. Tanida I, Ueno T, Kominami E. LC3 and Autophagy. Methods Mol Biol. 2008;445:77-88.
33. Ichimura Y, Komatsu M. Selective degradation of p62 by autophagy. Semin Immunopathol. 2010;32(4):431-6.
34. Staels B, Rubenstrunk A, Noel B, Rigou G, Delataille P, Millatt LJ, et al. Hepatoprotective effects of the dual peroxisome proliferator-activated receptor alpha/delta agonist, GFT505, in rodent models of nonalcoholic fatty liver disease/nonalcoholic steatohepatitis. Hepatology. 2013;58(6):1941-52.
35. Henao-Mejia J, Elinav E, Jin C, Hao L, Mehal WZ, Strowig T, et al. Inflammasome-mediated dysbiosis regulates progression of NAFLD and obesity. Nature. 2012;482(7384):179-85.
36. Hassoun E, Mettling C. Dichloroacetate and Trichloroacetate Toxicity in AML12 Cells: Role of Oxidative Stress. J Biochem Mol Toxicol. 2015; doi:10.1002/jbt.21720
37. Kleiner DE, Brunt EM, Van Natta M, Behling C, Contos MJ, Cummings OW, et al. Design and validation of a histological scoring system for nonalcoholic fatty liver disease. Hepatology. 2005;41(6):1313-21.